Skip to main content
  • SAPIEN 3 TAVR Shows Non-Inferiority to SAVR in Intermediate-Risk Patients: 5-Year Follow-Up Data

    SAPIEN 3 transcatheter aortic valve replacement (TAVR) is non-inferior to surgical aortic valve replacement (SAVR) in intermediate-risk patients with severe aortic stenosis at 5 years, according to mid-term follow-up data.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details